Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 EPS Loss of $0.08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Research and development: 2.41M
Today's EPS Names:
PFBX, GOVB, VABK, More
Financial Fact:
Research and development: 2.41M
Today's EPS Names:
PFBX, GOVB, VABK, More
Join SI Premium – FREE
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q2 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $190 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Bayfirst Financial Corp (BAFN) Tops Q3 EPS by 4c
- FTI Consulting (FCN) Tops Q3 EPS by 110c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
